BATTALION OIL CORP·4

Jul 17, 5:11 PM ET

Martin Charles E 4

4 · BATTALION OIL CORP · Filed Jul 17, 2026

Research Summary

AI-generated summary of this filing

Updated

Battalion Oil (BATL) VP/Controller Martin Charles E Receives RSU Award

What Happened

  • Martin Charles E, Vice President and Controller of Battalion Oil Corp (BATL), received an award of 68,154 restricted stock units (RSUs) on July 15, 2026. The Form 4 shows the acquisition as an award (code A) with a reported price of $0.00 (no cash paid at grant). This is a compensation grant (derivative award), not an open‑market purchase.

Key Details

  • Transaction date: July 15, 2026; Form 4 filed July 17, 2026 (timely filing).
  • Amount: 68,154 RSUs reported as acquired at $0.00 (derivative award).
  • Vesting: RSUs vest in four equal annual installments beginning July 15, 2027 (per footnote).
  • Shares owned after transaction: Not specified in the filing.
  • Footnote: Each RSU represents a contingent right to receive one share of common stock upon vesting.
  • No indication of a 10b5-1 plan, tax withholding, or late filing in the report.

Context

  • RSUs are a form of equity compensation that convert into actual shares only as they vest; the grant itself does not represent immediate share ownership or a cash purchase/sale. Such awards are common executive compensation and do not by themselves indicate a buy/sell signal.

Insider Transaction Report

Form 4
Period: 2026-07-15
Martin Charles E
VP, Controller
Transactions
  • Award

    Restricted Stock Unit

    [F1]
    2026-07-15+68,15468,154 total
    Common Stock (68,154 underlying)
Footnotes (1)
  • [F1]The Reporting Person received an award of restricted stock units ("RSUs") granted on July 15, 2026. Each RSU represents a contingent right to receive one share of Issuer's common stock. The RSUs vest in four equal annual installments beginning July 15, 2027.
Signature
/s/ Walter R. Mayer, Attorney-in-fact|2026-07-17

Documents

1 file
  • 4
    tm2620781-1_4seq1.xmlPrimary

    OWNERSHIP DOCUMENT